{"schema_version":"secwatch.filing_event.v1","accession":"0000010795-25-000036","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.439567+00:00","generated_at":"2026-05-22T23:41:47.982470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BD Q2 fiscal 2025: Revenue $5.27B (+4.5%), GAAP EPS $1.07 (down 42% YoY), adj. EPS $3.35","bullets":["Revenue increased 4.5% as reported to $5.272B; organic growth 0.9%, currency-neutral growth 6.0%.","GAAP diluted EPS $1.07, down 42.2% YoY; adjusted diluted EPS $3.35, up 5.7% YoY.","Company updates full-year fiscal 2025 guidance and provides estimated tariff impact; specific numbers not detailed.","Announces intention to invest $2.5B in U.S. manufacturing capacity over next 5 years.","Business highlights include FDA clearances for Phasix ST Umbilical Hernia Patch and advanced microbiology solution."],"urls":{"canonical":"https://secwatch.observer/filing/0000010795-25-000036","json":"https://secwatch.observer/filing/0000010795-25-000036.json","markdown":"https://secwatch.observer/filing/0000010795-25-000036.md","text":"https://secwatch.observer/filing/0000010795-25-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000001079525000036/0000010795-25-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000001079525000036/bdx-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T23:41:47.982470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}